swerte 2 play

yilmazsavaskandag/iStock via Getty Images Flagstar Financial, Inc. ( NYSE: FLG ) is a small-cap bank with a market cap of roughly $4 billion. The company has seen its share price decline along with the rest of the market over the past few You Only Get 1 Chance To Retire, Join The #1 Retirement Service The Retirement Forum provides actionable ideals, a high-yield safe retirement portfolio, and macroeconomic outlooks, all to help you maximize your capital and your income. We search the entire market to help you maximize returns. Recommendations from a top 0.2% TipRanks author! Retirement is complicated, and you only get once chance to do it right. Don't miss out because you didn't know what was out there. We provide: Click for our discounted 2-week free trial! The Value Portfolio specializes in building retirement portfolios and utilizes a fact-based research strategy to identify investments. This includes extensive readings of 10Ks, analyst commentary, market reports, and investor presentations. He invests real money in the stocks he recommends. Analyst’s Disclosure: I/we have a beneficial long position in the shares of FLG either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.Bowlero Becomes Lucky Strike Entertainment: A Bold Rebrand for the Future

RALEIGH, N.C. — Bill Belichick, cutting the sleeves off an Alexander Julian plaid blazer. Bill Belichick, responding to boosters’ grinning back-slaps with a scowl and, “We’re on to Georgia Tech.” Bill Belichick, trying on Mack Brown’s old sideline puffy coat for size. Bill Belichick, being asked to shake the hand of a human dressed as a toaster pastry. Bill Belichick, adding the entire lacrosse team to the football roster to play special teams. Can you imagine? JONES ANGELL: “Welcome back everyone to Bill Belichick Live. Say, Bill, what’s your favorite appetizer here at Top of the Hill?” BELICHICK: “Yeah, I’m not going to discuss that.” North Carolina will miss out on all of that wonderful stuff if it doesn’t lock down a deal with Belichick to replace Brown as football coach, something that seemed imminent over the weekend but continues to dangle in the breeze. North Carolina should be so lucky as to have it fall apart. This already has disaster written all over it, from the too-many-cooks hiring process to the transparent competing leaks from each camp: Belichick to NFL insiders, the trustees and boosters to political reporters. This circus has a lot of clowns and no tent. Just when you think things couldn’t possibly get any more absurd at North Carolina than Brown burning a career’s worth of bridges in Chapel Hill by insisting he would be back next season only to be informed the next day he would not, here comes an NFL legend who couldn’t land an NFL job last cycle, with absolutely no NCAA experience in that lengthy career, as the top candidate to replace him. Imagine the kind of privileged bubble you’d have to live in to be able to convince yourself that, after firing a genial 73-year-old coach who seemed to be losing his grasp on the rapidly changing world of college football, a surly 72-year-old with little or no grasp on college football is the right guy to replace him. Why not dig up Knute Rockne’s corpse and drag it around, like Weekend at Bernie’s? This is such a bad idea that even if it were to happen and somehow work out, it would still be an objectively bad idea even with 20-20 hindsight. Even if no one else wants the job, whether for football reasons or having to submit TPS reports to eight different bosses, this is an absurd place to land. North Carolina is willing to settle for someone who counts as family because his dad was a Tar Heels assistant coach for three years some 70 years ago, who has spent one fall observing his son as an assistant coach at Washington and is therefore an expert on the college game despite actually never coaching in it, whose NFL dynasty fizzled as soon as Tom Brady tapped out, whose coaching tree has had little success. (Two branches of it actually sprouted in the ACC: Al Groh and Bill O’Brien). And forget about UNC for a second: With all the nonsense that comes along with being a college head coach, it’s fair to wonder whether Belichick has fully thought this through, either. Two words: Mayo bath. What’s in this for him? If he wants to prove his late decline in New England wasn’t a fluke, the NFL is the place to do that. Beating Charlotte doesn’t count toward breaking Don Shula’s record. Beating the Panthers does. Brown may have been out of coaching for a little while when he returned to North Carolina, but he at least had won something at the NCAA level, knew the school inside and out and was (and remains) as avuncular as Belichick is gruff. Once again, the folks in power at North Carolina fell in love with a big-name trophy coach, but Belichick’s name only means anything to people like them. The oldest recruits in this cycle were 12 years old when Belichick last won anything. These kids don’t even know who he is, other than maybe the guy whose dog was apparently drafting for him during COVID. In Belichick’s defense, he does know the game of football as well as anyone on the planet and wouldn’t take the job without the financial backing to buy a decent team — no doubt at the continued expense of funds for basketball, which just lost out on the nation’s top recruit to BYU of all places — and if he’s got any tricks left up his absent sleeves, he might be able to find inefficiencies in recruiting, the transfer portal and on the field that college coaches have heretofore missed. It’s not like there are any NCAA rules left to break. But that’s a lot of maybes, and there are fundamental aspects of the college game — like sucking up to high-school coaches, making nice with the faculty and getting players out of the film room to go to class — that would be entirely foreign to Belichick. Whereas an up-and-coming college coach might have been able to build on the foundation Brown left behind — Jeff Monken is still out there, and wouldn’t it be something if UNC eventually blundered into what might be the best possible hire — this feels like it would be a ground-up rebuild of the entire operation. If Belichick really did submit a 400-page blueprint, and nothing’s ever gone wrong with a lengthy manifesto from a guy known for wearing a hoodie, it certainly suggests so. There are only two reasons someone like Belichick wants a job like this: He’s running away from something, or he’s got no place else to go. Unlike Norman Dale at Hickory High, there’s no Jimmy Chitwood waiting in the wings to save him. If this falls through, both sides should be relieved, not aggrieved. ©2024 The News & Observer. Visit at newsobserver.com . Distributed at Tribune Content Agency, LLC.John Longmire steps down as coach of Sydney Swans

Oklahoma's State Department of Education has proposed new standards for instruction within some social science lessons at the K-12 level which would base teaching on biblical ideals . The new standards would impact the teaching of lessons in history, geography, economics and civics instruction, reported The Duncan Banner . They would outline topics that Oklahoma schools are required to teach, but how they are taught and how lesson plans are developed is up to the staff of each institution. Officials supporting the new standards are aiming to have them approved by the Oklahoma State Board of Education and the state Legislature by 2025, when the standards for instruction in social studies and science lessons will be reviewed. Oklahoma's academic standards are up for review every six years. "Oklahoma is putting the Bible and the historical impact of Christianity back in school,"State Superintendent Ryan Walters said. "We are demanding that our children learn the full and true context of our nation's founding and of the principles that made and continue to make America great and exceptional." Walters has wanted to "eradicate radical woke influences" since he assumed the role of Superintendent. He stated that public school classrooms must all have a copy of the Bible earlier this year, further ordering that Biblical teachings be incorporated into history, literature and fine arts lessons. Furthermore, his administration spent $25,000 on copies of Lee Greenwood's God Bless the USA Bible, which were then distributed to local schools. "These new standards fully and unabashedly answer the mandate that voters demanded upon electing President Trump: no more woke, radical indoctrination. No more racially divisive, hyper sexualized, watered down, weak curriculum that has left us with the worst public education outcomes in our history," Walters said. The new standards are still open to comments and criticism from the public. Originally published by Latin Times.TORONTO, ON — Two Canadian Cabinet ministers met with President-elect Donald Trump's nominee for commerce secretary at Mar-a-Lago on Friday as Canada tries to avoid sweeping tariffs when Trump takes office. Finance Minister Dominic LeBlanc and Foreign Minister Mélanie Joly met with Howard Lutnick, Trump’s nominee for commerce secretary, as well as North Dakota Gov. Doug Burgum, Trump’s pick to lead the Interior Department. Trump has threatened to impose 25% tariffs on all Canadian products if Canada does not stem what he calls a flow of migrants and fentanyl into the United States — even though far fewer of each cross into the U.S. from Canada than from Mexico, which Trump has also threatened. “Minister LeBlanc and Minister Joly had a positive, productive meeting at Mar-a-Lago with Howard Lutnick and Doug Burgum, as a follow-up to the dinner between the Prime Minister and President Trump last month,” said Jean-Sébastien Comeau, a spokesman for LeBlanc. Comeau said both ministers outlined the measures in Canada's billion-dollar plan to increase security at the border and reiterated “the shared commitment to strengthen border security as well as combat the harm caused by fentanyl to save Canadian and American lives.” Comeau said Lutnick and Burgum agreed to relay the information to Trump. The Trump transition team did not immediately respond to a message seeking comment. Further discussions are expected in the coming weeks. Joly will also have dinner with U.S. Sen. Lindsey Graham on Friday. Trump has been trolling Prime Minister Justin Trudeau on social media in recent weeks by calling him the Governor of the 51st state. Trudeau has not directly responded, but did post a link Thursday to a six-minute video on YouTube from 2010 in which American NBC journalist Tom Brokaw “explains Canada to Americans.” “Some information about Canada for Americans” Trudeau wrote in the post on X. The video, which originally aired during the 2010 Vancouver Olympics, explains similarities between the two countries, the massive trading relationship and the actions of the Canadian military in World War 2 and Afghanistan. “In our darkest hours Canada has been with us,” Brokaw says in the video. “In the long history of sovereign neighbors there has never been a relationship as close, productive and peaceful as the U.S. and Canada.” Trudeau has told Trump that Americans would also suffer if the president-elect follows through on a plan to impose sweeping tariffs on Canadian products . About 60% of U.S. crude oil imports and 85% of U.S. electricity imports are from Canada. Alberta alone sends 4.3 million barrel s of oil per day to the U.S which tends to consume about 20 million barrels a day. Trump has also made an issue of the U.S. trade deficit with Canada, erroneously calling it a subsidy. Canada’s ambassador to Washington, Kirsten Hillman, has said the U.S. had a $75 billion trade deficit with Canada last year. But she noted a third of what Canada sells into the U.S. are energy exports and said there is a deficit when oil prices are high. Nearly $3.6 billion Canadian dollars ($2.7 billion) worth of goods and services cross the border each day. Canada is the top export destination for 36 U.S. states. Flows of migrants and seizures of drugs are vastly different at the U.S.’s two land borders. U.S. customs agents seized 43 pounds of fentanyl at the Canadian border during the last fiscal year, compared with 21,100 pounds at the Mexican border. Most of the fentanyl reaching the U.S. — where it causes about 70,000 overdose deaths annually — is made by Mexican drug cartels using precursor chemicals smuggled from Asia. On immigration, the U.S. Border Patrol reported 1.53 million encounters with migrants at the southwest border with Mexico between October 2023 and September 2024. That compares to 23,721 encounters at the Canadian border during that time.

Airports and highways are expected to be jam-packed during Thanksgiving week.

NEW YORK , Dec. 12, 2024 /PRNewswire/ -- Report with market evolution powered by AI - The global biologics contract development and manufacturing organization (CDMO) market size is estimated to grow by USD 10.63 billion from 2024-2028, according to Technavio. The market is estimated to grow at a CAGR of 10.46% during the forecast period. Availability of cost-efficient resources in emerging markets is driving market growth, with a trend towards advent of big data. However, capacity utilization and constraints poses a challenge. Key market players include 3P BIOPHARMACEUTICALS S.L.U, AbbVie Inc., AGC Biologics, Binex Co. Ltd., Boehringer Ingelheim International GmbH, Bora Pharmaceuticals Co. Ltd, Catalent Inc., Evonik Industries AG, FUJIFILM Corp., Grifols SA, J RETTENMAIER and SOHNE GmbH and Co KG, JSR Corp., Kemwell Biopharma Pvt. Ltd., Lonza Group Ltd., Novartis AG, Rentschler Biopharma SE, Samsung Electronics Co. Ltd., Shenzhen Hepalink Pharmaceutical Co. Ltd., Toyobo Co. Ltd., and WuXi Biologics Cayman Inc.. AI-Powered Market Evolution Insights. Our comprehensive market report ready with the latest trends, growth opportunities, and strategic analysis- View Free Sample Report PDF Forecast period 2024-2028 Base Year 2023 Historic Data 2018 - 2022 Segment Covered Type (Mammalian and Microbial), Product Type (Biologics and Biosimilars), and Geography (North America, Europe, Asia, and Rest of World (ROW)) Region Covered North America, Europe, Asia, and Rest of World (ROW) Key companies profiled 3P BIOPHARMACEUTICALS S.L.U, AbbVie Inc., AGC Biologics, Binex Co. Ltd., Boehringer Ingelheim International GmbH, Bora Pharmaceuticals Co. Ltd, Catalent Inc., Evonik Industries AG, FUJIFILM Corp., Grifols SA, J RETTENMAIER and SOHNE GmbH and Co KG, JSR Corp., Kemwell Biopharma Pvt. Ltd., Lonza Group Ltd., Novartis AG, Rentschler Biopharma SE, Samsung Electronics Co. Ltd., Shenzhen Hepalink Pharmaceutical Co. Ltd., Toyobo Co. Ltd., and WuXi Biologics Cayman Inc. Key Market Trends Fueling Growth The Biologics Contract Development and Manufacturing Organization (CDMO) market is experiencing significant growth, particularly in the areas of small molecules and large molecules, including biologics, biosimilars, cancer therapies, monoclonal antibodies, and vaccines. This trend is driven by the increasing demand for specialized expertise and advanced technology in the production of complex biological medicinal products. Niche CDMOs and biopharmaceutical CDMOs are leading the way in the production of biologics, such as recombinant proteins and monoclonal antibodies, using cutting-edge technology like advanced manufacturing technologies, single-use/disposable bioreactors, and automation. The focus on infectious diseases, chronic diseases, and novel therapies, such as immunotherapy, is also driving growth in the market. The disease landscape is constantly evolving, with an increasing focus on evidence-based practice and the development of treatments for conditions like diabetes, geriatric population, and metabolic illnesses. Supply chain management, quality testing, and third-party logistic providers are essential components of the CDMO market, ensuring the production of high-quality biological medications and vaccinations. The use of advanced technology, such as software development and process engineering, is crucial for the production of complex biological molecules, including nucleic acids, cell receptors, and post-translational changes. Pharma clients require CDMOs to provide clinical services, from fermentation and tissue processing to cell bank creation and cell line engineering. The production of biological medications and vaccinations requires a deep understanding of biology, as well as expertise in areas like myelosuppression, cardiotoxicity, renal insufficiency, and neurotoxicity. The CDMO market is expected to continue growing, with a focus on the production of small-molecule drugs, biopharmaceuticals, and biological medications, as well as the development of novel therapies for diseases like allergies, gene therapy, and metabolic syndrome. The use of advanced technology, specialized expertise, and niche CDMOs will be key to meeting the demands of the market and delivering high-quality products to patients. The pharmaceutical industry's technological advancements extend beyond drug research and development to data analytics. This tool is increasingly utilized for clinical data synthesis, expediting the drug development process. Big data is a popular strategy in healthcare, including pharmaceuticals, for informed research and development decisions. Data analytics effectively identifies potential new drug candidates, creates simulation models to assess drug efficacy, pinpoints patient populations through various sources, and monitors potential side effects for early avoidance. Biologics Contract Development and Manufacturing Organizations (CDMOs) leverage these analytics to streamline their services, ensuring efficient and effective drug development. Insights on how AI is driving innovation, efficiency, and market growth- Request Sample! Market Challenges Insights into how AI is reshaping industries and driving growth- Download a Sample Report Segment Overview This biologics contract development and manufacturing organization (cdmo) market report extensively covers market segmentation by 1.1 Mammalian- The mammalian segment holds a significant share in the global biologics Contract Development and Manufacturing Organization (CDMO) market due to the increasing use of mammalian cells in producing therapeutic proteins for various diseases. Mammalian cells, derived from mammalian tissue, are primarily used for growing animal cells in vitro, and there are four main types: fibroblasts, epithelial cells, lymphocytes, and macrophages. Lymphocytes are found in the blood, while the others are found in tissue. Mammalian cell culture is widely used for producing human proteins with high therapeutic potential, such as tissue plasminogen activators, clotting factors, and erythropoietin, which cannot be produced using bacteria or yeasts. Recombinant proteins from mammalian cells are used in therapeutics for conditions like diabetes and cancer. Additionally, mammalian cell culture technology is utilized for bulk vaccine production, contributing to market growth. For instance, Catalent Inc. Signed an agreement in June 2020 to develop a COVID-19 vaccine using its GPEx cell line development technology. Catalent offers comprehensive services, including mammalian cell line development, process development, process validation, formulation development, and drug substance manufacturing, from preclinical to commercial stages. These factors are expected to drive the growth of the mammalian segment in the global biologics CDMO market. Download complimentary Sample Report to gain insights into AI's impact on market dynamics, emerging trends, and future opportunities- including forecast (2024-2028) and historic data (2018 - 2022) Research Analysis The Biologics Contract Development and Manufacturing Organization (CDMO) market caters to the production of Biological Medicinal Products, including large molecules such as monoclonal antibodies, biosimilars, cancer therapies, and small molecules. These CDMOs play a crucial role in supplying the pharma industry with high-quality products, serving clients in various therapeutic areas like chronic infectious diseases and diabetes. Advanced manufacturing technologies, like single-use/disposable bioreactors, automation, and software development, are transforming the industry. Smaller, niche BioCDMOs also thrive, offering specialized services in areas like tissue processing and clinical services. The focus on quality testing ensures the production of safe and effective biological medicines, meeting regulatory requirements. Biopharmaceutical companies benefit from the expertise and capabilities of these CDMOs, streamlining their supply chain and accelerating time-to-market for new treatments. Market Research Overview The Biologics Contract Development and Manufacturing Organization (CDMO) market encompasses the production of biologics, including small molecules, large molecules, biosimilars, monoclonal antibodies, cancer therapies, and various specialized therapies such as vaccines, recombinant proteins, and novel therapies. This market caters to the supply chain needs of pharmaceutical clients, focusing on quality testing, third-party logistic providers, and advanced technology. Biologics CDMOs offer specialized expertise in areas like fermentation, microbial fermentation, and advanced manufacturing technologies, including single-use/disposable bioreactors. The market landscape includes a range of niche and biopharmaceutical CDMOs, serving various disease areas like infectious diseases, chronic diseases, and cancer. Cutting-edge technology and evidence-based practice are integral to the biologics CDMO sector, which includes the production of biological medicinal products, small-molecule drugs, and biopharmaceuticals. The biology of cells, tissue processing, cell bank creation, cell line engineering, and post-translational changes are crucial aspects of biologics production. The geriatric population, with ageing and multisystem functional decline, presents unique challenges, including myelosuppression, cardiotoxicity, renal insufficiency, neurotoxicity, polypharmacy, and mental state. Biologics CDMOs address these challenges through automation, software development, process engineering, and biology expertise. The biologics CDMO sector also covers the production of vaccinations, somatic cells, tissues, and various biological molecules, including nucleic acids, cell receptors, and metabolic illnesses like diabetes. Allergy treatments, gene therapy, and therapies for various diseases like cancer, infectious diseases, and metabolic syndrome are also part of the biologics CDMO market. Table of Contents: 1 Executive Summary 2 Market Landscape 3 Market Sizing 4 Historic Market Size 5 Five Forces Analysis 6 Market Segmentation 7 Customer Landscape 8 Geographic Landscape 9 Drivers, Challenges, and Trends 10 Company Landscape 11 Company Analysis 12 Appendix About Technavio Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios. Contacts Technavio Research Jesse Maida Media & Marketing Executive US: +1 844 364 1100 UK: +44 203 893 3200 Email: media@technavio.com Website: www.technavio.com/ View original content to download multimedia: https://www.prnewswire.com/news-releases/biologics-cdmo-market-to-grow-by-usd-10-63-billion-from-2024-2028--report-on-ai-redefining-market-landscape-and-cost-efficient-resources---technavio-302328830.html SOURCE Technavio

Players Era Festival organizers betting big NIL is future of college tourneys

Supporters of suspected CEO killer Luigi Mangione establish defense fundInfluencer arrested for faking single father story with toddler, 400k followers deceived

‘Christmas Light Fight’ Host Carter Oosterhouse on Holiday Traditions, Marriage to Amy Smart & More

Schneider National, Inc. ( NYSE:SNDR – Get Free Report ) insider Shaleen Devgun sold 10,000 shares of Schneider National stock in a transaction dated Friday, December 20th. The shares were sold at an average price of $29.04, for a total value of $290,400.00. Following the completion of the sale, the insider now owns 95,191 shares of the company’s stock, valued at $2,764,346.64. The trade was a 9.51 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link . Schneider National Stock Down 0.2 % NYSE:SNDR opened at $29.54 on Friday. The company’s 50 day moving average is $30.40 and its two-hundred day moving average is $27.55. The company has a market cap of $5.17 billion, a PE ratio of 47.65, a P/E/G ratio of 3.24 and a beta of 0.90. Schneider National, Inc. has a twelve month low of $20.50 and a twelve month high of $33.90. The company has a current ratio of 1.66, a quick ratio of 1.53 and a debt-to-equity ratio of 0.04. Schneider National ( NYSE:SNDR – Get Free Report ) last released its earnings results on Wednesday, November 6th. The company reported $0.18 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.23 by ($0.05). Schneider National had a net margin of 2.10% and a return on equity of 3.92%. The firm had revenue of $1.32 billion during the quarter, compared to analyst estimates of $1.33 billion. Analysts anticipate that Schneider National, Inc. will post 0.7 EPS for the current year. Schneider National Dividend Announcement Institutional Investors Weigh In On Schneider National Large investors have recently bought and sold shares of the company. Innealta Capital LLC acquired a new stake in Schneider National during the 2nd quarter valued at approximately $53,000. DekaBank Deutsche Girozentrale purchased a new stake in Schneider National in the third quarter valued at $73,000. Quarry LP acquired a new stake in Schneider National during the 3rd quarter worth about $90,000. SG Americas Securities LLC acquired a new stake in Schneider National during the 3rd quarter worth about $109,000. Finally, Hills Bank & Trust Co acquired a new position in shares of Schneider National in the 3rd quarter valued at about $112,000. Hedge funds and other institutional investors own 28.54% of the company’s stock. Analysts Set New Price Targets Several equities research analysts have recently commented on the stock. Bank of America boosted their price target on shares of Schneider National from $35.00 to $38.00 and gave the company a “buy” rating in a report on Tuesday, November 26th. The Goldman Sachs Group dropped their target price on Schneider National from $26.00 to $25.00 and set a “neutral” rating on the stock in a research report on Wednesday, October 9th. Evercore ISI reduced their price target on Schneider National from $27.00 to $26.00 and set an “in-line” rating for the company in a research report on Thursday, November 7th. TD Cowen raised their price objective on Schneider National from $32.00 to $34.00 and gave the company a “buy” rating in a research report on Tuesday, November 26th. Finally, Stifel Nicolaus boosted their target price on shares of Schneider National from $25.00 to $27.00 and gave the stock a “hold” rating in a report on Monday, November 11th. One research analyst has rated the stock with a sell rating, eight have given a hold rating and five have issued a buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $29.08. Read Our Latest Analysis on Schneider National Schneider National Company Profile ( Get Free Report ) Schneider National, Inc, together with its subsidiaries, provides surface transportation and logistics solutions in the United States, Canada, and Mexico. It operates through three segments: Truckload, Intermodal, and Logistics. The Truckload segment offers over the road freight transportation services primarily through dry van, bulk, temperature-controlled, and flat-bed trailers across either network or dedicated configurations. Recommended Stories Receive News & Ratings for Schneider National Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Schneider National and related companies with MarketBeat.com's FREE daily email newsletter .

LAS VEGAS — Players Era Festival organizers have done what so many other have tried — bet their fortunes in this city that a big payoff is coming. Such bet are usually bad ones, which is why so many massive casino-resorts have been built on Las Vegas Boulevard. But it doesn't mean the organizers are wrong. They're counting on the minimum of $1 million in guaranteed name, image and likeness money that will go to each of the eight teams competing in the neutral-site tournament that begins Tuesday will create a precedent for other such events. EverWonder Studios CEO Ian Orefice, who co-founded Players with former AND1 CEO Seth Berger, compared this event to last year's inaugural NBA In-Season Tournament that played its semifinals and final in Las Vegas by saying it "did really well to reinvigorate the fan base at the beginning of the year." People are also reading... "We're excited that we're able to really change the paradigm in college basketball on the economics," Orefice said. "But for us, it's about the long term. How do we use the momentum that is launching with the 2024 Players Era Festival and be the catalyst not to change one event, but to change college basketball for the future." Orefice and Berger didn't disclose financial details, but said the event will come close to breaking even this year and that revenue is in eight figures. Orefice said the bulk of the revenue will come from relationships with MGM, TNT Sports and Publicis Sport & Entertainment as well as sponsors that will be announced later. Both organizers said they are so bullish on the tournament's prospects that they already are planning ahead. Money made from this year's event, Orefice said, goes right back into the company. "We're really in this for the long haul," Orefice said. "So we're not looking at it on a one-year basis." Rick Giles is president of the Gazelle Group, which also operates several similar events, including the College Basketball Invitational. He was skeptical the financial numbers would work. Giles said in addition to more than $8 million going to the players, there were other expenses such as the guarantees to the teams. He said he didn't know if the tournament would make up the difference with ticket sales, broadcast rights and sponsorship money. The top bowl of the MGM Grand Garden Arena will be curtained off. "The math is highly challenging," Giles said. "Attendance and ticket revenues are not going to come anywhere close to covering that. They haven't announced any sponsors that I'm aware of. So it all sort of rests with their media deal with Turner and how much capital they want to commit to it to get these players paid." David Carter, a University of Southern California adjunct professor who also runs the Sports Business Group consultancy, said even if the Players isn't a financial success this year, the question is whether there will be enough interest to move forward. "If there is bandwidth for another tournament and if the TV or the streaming ratings are going to be there and people are going to want to attend and companies are going to want to sponsor, then, yeah, it's probably going to work," Carter said. "But it may take them time to gain that traction." Both founders said they initially were met with skepticism about putting together such an event, especially from teams they were interested in inviting. Houston was the first school to commit, first offering an oral pledge early in the year and then signing a contract in April. That created momentum for others to join, and including the No. 6 Cougars, half the field is ranked. "We have the relationships to operate a great event," Berger said. "We had to get coaches over those hurdles, and once they knew that we were real, schools got on board really quickly." The founders worked with the NCAA to make sure the tournament abided by that organization's rules, so players must appear at ancillary events in order to receive NIL money. Strict pay for play is not allowed, though there are incentives for performance. The champion, for example, will receive $1.5 million in NIL money. Now the pressure is on to pull off the event and not create the kind of headlines that can dog it for years to come. "I think everybody in the marketplace is watching what's going to happen (this) week and, more importantly, what happens afterwards," Giles said. "Do the players get paid on a timely basis? And if they do, that means that Turner or somebody has paid way more than the market dictates? And the question will be: Can that continue?" CREIGHTON: P oint guard Steven Ashworth likely won’t play in the No. 21 Bluejays’ game against San Diego State in the Players Era Festival in Las Vegas. Ashworth sprained his right ankle late in a loss to Nebraska on Friday and coach Greg McDermott said afterward he didn’t know how long he would be out. Get local news delivered to your inbox!Two major automakers are joining forces to survive

CIA 'Greatly Complicated' Havana Syndrome Treatment: Senate